The vaccine is the kidney cancer patient's new hope

Cancer vaccine therapy drive put forward already sometimes the day be a bio-chemical and genetic engineering and 2 technically combine and is use to study cure of melanin lump, mammary glands cancer, prostate gland cancer, colon and rectum cancer at the earliest stage.Recently, kidney cancer the research of the vaccine made very big progress, have already carried on a human body treatment to experiment in the United States and Germany and have already ined the short term hope to walk up clinical, bring a new hope for the kidney cancer sufferer.

The kidney cancer is a kind of very unprogressive tumor, to the traditional chemotherapy, put to treat to almost have no reaction.The kidney cancer vaccine the therapy will take out from sufferer's body of tumor cell and dendrite form cell mutually blends and cure of vaccine infusion the sufferer is inside body, the immune system of the start sufferer's oneself resists tumor cell, can to the growth creation of the tumor deceleration, can also repress tumor cell to transfer toward other organs, even probably exterminate tumor cell but attain to make it contract, disappear of effect.

The clinical trial that the scientist of German Lyu3 Bei4 Ke4's university carries on to nearly 400 kidney cancer sufferers show that accept the patient of vaccine treatment, it five year, the existence rate is 77%, but didn't accept the patient of that treatment the existence rate is only 68% for five years.Only thered are 3% patients to take place some not serious side effect.They get the conclusion of be the development process that this kind of vaccine can effectively decelerate tumor, prevent°from surgical operation excision after the tumor a kidney cancer relapse, exaltation patient existence rate. And, vaccine to the tumor organize more and greatly, relapse a risk higher patient's effect be better.

Develop a kidney cancer the German manufacture technology company(LipoNova GmbH) of the vaccine have already put forward the kidney cancer vaccine batch quantity to produce, appear on market toward the European medicine administration in December, 2003, the application of clinical application, can in the short term acquire an approval.